



Natalie J. Torok, M.D., M.Sc.

Philosophy of Care

As a hepatologist and certified transplant hepatologist, I take care of patients with end-stage liver disease and also provide post-transplant care, including management of immunosuppression and treatment of post-transplant hepatitis C.

I see patients with nonalcoholic steatohepatitis (NASH), alcoholic liver disease, and autoimmune hepatitis. Also, we provide comprehensive care for patients with hepatocellular carcinoma.

Clinical Interests

Dr. Torok's clinical interests include; Gastroenterology and Hepatology, Transplant Hepatology, and Internal Medicine.

Research/Academic Interests

Our research focuses on wound healing and the basic mechanism of fibrosis in the liver. We explore the pathways linking chronic liver injury, hepatocyte death and the activation of hepatic stellate cells, the principle fibrogenic cells of the liver.

Our investigations led to the discovery of the important role of the NADPH oxidases in stellate cell activation and the production of oxidative radicals. Based on our findings our aim is to explore the specific role of NADPH oxidases in non-alcoholic steatohepatitis and alcoholic liver disease. Our ultimate goal is to move towards translational studies and to develop new therapies for patients with liver fibrosis and cirrhosis.

Title

Professor

Professor, VA Northern California Health Care System, Mather, CA

Specialty

Gastroenterology and Hepatology, Internal Medicine, Transplant Hepatology

Department

[Internal Medicine](#)

[UC Davis Medical Group](#)

Division

Gastroenterology and Hepatology

UC Davis Medical Group, Sacramento - Midtown

Clinic

UC Davis Medical Group, Folsom

Center/Program Affiliation

[UC Davis Medical Group](#)

Address/Phone

UC Davis Midtown Ambulatory Care Center, Midtown GI Clinic, 3160 Folsom Blvd Suite 3500
Sacramento, CA 95816

Phone: 916-734-0779

UC Davis Medical Group - Folsom, 271 Turn Pike Dr. Folsom, CA 95630

Phone: 916-985-9300



Natalie J. Torok, M.D., M.Sc.

Additional Phone	Physician Referrals: 800-4-UCDAVIS (800-482-3284)
Languages	French, Hungarian, Russian
Education	M.D., Semmelweis Medical University, Budapest, 1988 M.Sc., Cellular and Molecular Biology, Cancer Research Institute of Laval University, Quebec Canada 1992 B.Sc., Verseghy Gimnázium, Szolnok Hungary 1982
Residency	Semmelweis University, Budapest, 1988-1990 Internal Medicine, Mayo Clinic, Rochester MN 1996-1999
Fellowships	Gastroenterology and Hepatology, Mayo Clinic, Rochester MN 1999-2003
Board Certifications	American Board of Internal Medicine, 2010 American Board of Internal Medicine, Gastroenterology and Hepatology, 2014 American Board of Internal Medicine, Transplant Hepatology, 2008
Professional Memberships	American Association for the Study of Liver Disease American College of Physicians American Gastroenterological Association American Liver Foundation American Society for Clinical Investigation
Honors and Awards	Associate Editor, American Journal of Physiology, Gastrointestinal and Liver Physiology, 2015 Elected to the American Society for Clinical Investigation, 2014 Boris Ruebner and John Rosenquist Excellence in Teaching Award, UC Davis, GI and Hepatology, 2014 Richard C. Woodard Award, UC Davis Mentor, 2014 Internal Medicine-Pathology-Surgery Research Award, UC Davis, 2012 University of California, Cancer Research Coordinating Committee Award, 2006
Select Recent Publications	Torok NJ: Update on Alcoholic Hepatitis. <i>Biomolecules</i> , 2015 Nov 2;5(4):2978-86. Bettaieb A, Jiang JX, Sasaki Y, Chao TI, Kiss Z, Chen X, Tian J, Katsuyama M, Yabe-Nishimura C, Xi Y, Szyndralewicz C, Schröder K, Shah A, Brandes RP, Haj FG and Török NJ: "Hepatocyte NADPH Oxidase 4 Regulates Stress Signaling, Fibrosis, and Insulin Sensitivity during Development of Steatohepatitis in Mice", <i>Gastroenterology</i> , 2015;Aug;149(2):468-480.



Natalie J. Torok, M.D., M.Sc.

Torok NJ, JA. Dranoff, D. Schuppan and SL. Friedman: "Strategies and Endpoints of Antifibrotic Drug Trials" *Hepatology*, 2015;Aug;62(2):627-34.

Jiang JX, Torok NJ: "MLK3 as a regulator of disease progression in NASH". *Liver Int.* 2014 Apr 1.

Jiang XJ, Chen, X, Fukada, H, Serizawa, N, Devaraj, S, and Török, NJ: Advanced glycation end products induce fibrogenic activity in NASH by modulating the TNF α converting enzyme activity in mice. *Hepatology*, 2013, Oct;58(4):1339-48.

© 2017 UC Regents